Small protein changes may make big difference in natural HIV control
Variations in protein structure impact effectiveness of immune response
4-Nov-2010 - Tiny variants in a protein that alerts the immune system to the presence of infection may underlie the rare ability of some individuals
to control HIV infection without the need for medications. In a report that will appear in Science and is receiving early online release, an international research team led
by investigators from the Ragon Institute of Massachusetts General Hospital (MGH), MIT and Harvard and from the Broad Institute of MIT and Harvard describe finding that
differences in five amino acids in a protein called HLA-B are associated with whether or not HIV-infected individuals can control viral levels with their immune system only.
"We found that, of the three billion nucleotides in the human genome, just a handful make the difference between those who can stay healthy in spite
of HIV infection and those who, without treatment, will develop AIDS," says Bruce Walker, MD, director of the Ragon Institute and co-senior author of the Science
article. "Understanding where this difference occurs allows us to sharpen the focus of our efforts to ultimately harness the immune system to defend against HIV."
"Earlier studies had showed that certain genes involved with the HLA system were important for HIV control," adds Paul de Bakker, PhD, of
the Broad Institute and Brigham and Women's Hospital, co-senior author. "But they couldn't tell us exactly which genes were involved and how they produced this difference.
Our findings take us not only to a specific protein, but to a part of that protein that is essential to its function."
It has been known for almost two decades that a small minority - about one in 300 - of individuals infected with HIV are naturally able to suppress
viral replication with their immune system, keeping viral load at extremely low levels. To identify genetic differences that may underlie this rare ability, Florencia Pereyra,
MD, at the Ragon Institute established the International HIV Controllers Study ( http://www.hivcontrollers.org/ )
in 2006, with a goal of enrolling 1,000 HIV controllers from medical clinics and research institutes around the world. That goal was expanded to 2,000 controllers in 2008, and
thus far over 1,500 controllers have been enrolled.
The current investigation began with a genome-wide association study (GWAS) of almost 1,000 controllers and 2,600 individuals with progressive HIV infection, through a
collaboration with the AIDS Clinical Trials Group. The GWAS, which tests variations at a million points in the human genome, identified some 300 sites that were
statistically associated with immune control of HIV, all in regions of chromosome 6 that code for HLA proteins. Further analysis narrowed the number of gene
sites to four but could not indicate whether those differences actually affected viral control or were just located near the causal variants. Fully
sequencing that genome region in all participants was not feasible, but a process developed by Sherman Jia - a medical student in the
Harvard-MIT Health Sciences and Technology program, working with de Bakker at the Broad - pinpointed specific amino acids; and
directly testing those sites associated five amino acids in the HLA-B protein with differences in viral control.
HLA-B is essential to the process by which the immune system recognizes and destroys virus-infected cells. Usually HLA-B grabs onto viral protein segments called peptides that are inside
the cell and carries them to the cell membrane where they essentially flag the infected cell for destruction by CD8 "killer" T cells. The portion of the HLA-B protein that grabs and
displays viral peptides is called the binding pocket, and all of the five identified amino acid sites are in the lining of the binding pocket.
"Amino acid variation within the HLA-B binding pocket will impact its shape and structure, probably resulting in some peptides being presented effectively and others not," de
Bakker says. "Our work demonstrates that these variants could make a crucial difference in the individual's ability to control HIV by changing how HLA-B presents peptides from this
virus to the immune system."
Walker adds, "HIV is slowly revealing its secrets, and this is yet another. Knowing how an effective immune response against HIV is generated is an important step
toward replicating that response with a vaccine. We have a long way to go before translating this into a treatment for infected patients and a vaccine to prevent infection, but we
are an important step closer."
The investigators note that these findings would not have been possible without the participation of the hundreds of HIV controllers, many of whom traveled to
Boston for testing, who have enrolled in the study. "The enthusiasm among the patients we have enrolled and the HIV providers who referred them has been
amazing," says Pereyra. "They tell us that being part of this collaborative study means a lot to them."
Original support for the International HIV Controllers study came through a 2006 grant from the Mark and Lisa Schwartz Foundation, and the study was expanded in 2008 through the support
of the Bill and Melinda Gates Foundation. Additional supporting agencies include the Harvard Center for AIDS Research and the National Institutes of Health.
Walker is a professor and de Bakker an assistant professor of Medicine at Harvard Medical School. Under the leadership of Pereyra, more than 300 investigators at over 200 institutions
around the world contributed to the Science study. Study co-authors include, among others, Steven Deeks, MD, University of California, San Francisco; Amalio Telenti, MD, PhD,
University of Lausanne, Switzerland; Mary Carrington, PhD, National Institutes of Health; Vincent Marconi, MD, Emory University; David Haas, MD, Vanderbilt University; John Fangman,
MD, AIDS Resource Center of Wisconsin: Martin Markowitz, MD, Aaron Diamond AIDS Research Center; Richard Harrigan, PhD, British Columbia Centre for Excellence in HIV/AIDS; James Braun,
DO, Physicians Research Network, New York; Ronald Nahass, MD, I.D. Care Associates, Hillsborough, New Jersey: and Otto O. Yang, MD, University of California. Los Angeles.
The Eli and Edythe L. Broad Institute of MIT and Harvard was founded in 2003 to empower this generation of creative scientists to transform medicine with new genome-based knowledge.
The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new
approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community. Founded by MIT, Harvard and its
affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students
from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions
in more than 40 countries worldwide. For further information about the Broad Institute, go to www.broadinstitute.org .
The Ragon Institute of MGH, MIT and Harvard was established in 2009 with a gift from the Philip T. and Susan M. Ragon Foundation, creating a collaborative scientific mission among these
institutions to harness the immune system to combat and cure human diseases. The primary initial focus of the institute is to contribute to the development of an effective AIDS vaccine.
The Ragon Institute draws scientists and engineers from diverse backgrounds and areas of expertise across the Harvard and MIT communities and throughout the world, in order to apply
the full arsenal of scientific knowledge to understanding mechanisms of immune control and immune failure and to apply these advances to directly benefit patients. For further
information visit www.ragoninstitute.org .
Contact: Sue McGreevey
Massachusetts General Hospital